ArticleBMC infectious diseases2025
Difference of clinical characteristics in patients with reinfection and primary infection variants of SARS-CoV-2: a retrospective study in China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of patients experiencing re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is progressively increasing. In this study, we aimed to explore the differences in clinical characteristics between patients with primary infection and those with re-infection of SARS-CoV-2.
methodsA retrospective data analysis was conducted involving patients diagnosed with coronavirus disease 2019 between April 1, 2023, and June 20, 2023. The patients were categorized into two groups: the observation group, consisting of individuals re-infected with SARS-CoV-2, and the control group, comprising those with primary SARS-CoV-2 infection.
resultsA total of 905 (905/1025) patients were included in the study, with 407 in the observation group and 498 in the control group. The top three clinical symptoms in both groups were fever, cough with expectoration, and dizziness with fatigue (p < 0.001). The clinical classification of patients in the observation group primarily consisted of non-severe cases (p < 0.001). The proportion of hospitalized patients was lower in the observation group than in the control group (p < 0.001). The observation group exhibited a shorter clinical symptom recovery time than that did the control group (median, 5 days vs. 7 days, Log rank p<0.001, HR = 1.907(95% CI 1.669-2.178).
conclusionsPatients experiencing SARS-CoV-2 re-infection were primarily classified as non-severe cases, with lower proportions of occurrence of severe and rare critical conditions. The severity was milder compared to that in patients with primary SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.